NORD and 86 other organizations oppose the Senate including changes to the Orphan Drug Tax Credit in the Build Back Better Act
Read full statement >NORD and 86 other organizations ask for the removal of provisions related to the Orphan Drug Tax Credit in the House version of the Build Back Better Act
Read full statement >NORD letter to House Ways & Means Committee opposing Section 138141 of the Build Back Better Act
Read full statement >NORD submits comments on FDA Draft Guidance on Interpreting Sameness for Gene Therapy Products Under the Orphan Drug Regulations
Read full statement >NORD comments to FDA regarding its definition of low-prevalence in a recent draft guidance
Read full statement >NORD comments to the American Medical Association expressing concerns with their resolution proposing reforms to the ODA
Read full statement >